NCT04765228Unknown2 期
A Prospective One-arm Study of Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Locally Advanced Soft Tissue Sarcoma
Yong Chen1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2020年4月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- ORR
研究概览
简要总结
A prospective one-arm study of pegylated liposomal doxorubicin combined with anlotinib for neoadjuvant treatment of locally advanced soft tissue sarcoma.
详细描述
Tumor angiogenesis is very important in the occurrence and development of soft tissue sarcoma. The current clinical studies of molecularly targeted drugs are focused on the advanced treatment stage of soft tissue sarcoma. Anti-angiogenic drugs are not yet available in the neoadjuvant treatment stage of soft tissue sarcoma. Strong evidence. Therefore, this study aimed to evaluate the safety and effectiveness of pegylated doxorubicin liposomes combined with the anti-angiogenic drug Anlotinib for neoadjuvant treatment of patients with soft tissue sarcoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 14 Years 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with soft tissue sarcoma confirmed by histopathology;
- •Patients with soft tissue sarcoma judged to be stage IIB/III according to the AJCC staging of soft tissue sarcoma, or tumors that are closely related to important blood vessels and important nerves suggested by imaging data;
- •No distant transfer
- •According to the preliminary judgment of the research, patients who can improve the effect of surgery by neoadjuvant treatment;
- •Male or female, aged ≥14 years old and ≤75 years old;
- •ECOG score ≤ 2;
- •The expected survival period is ≥3 months;
- •Adequate hematopoietic function: absolute neutrophil count (ANC) ≥ 1.5×109/L and platelet count ≥ 80×109/L and hemoglobin ≥ 9 g/dL;
- •Sufficient liver function: total bilirubin ≤ upper limit of normal (ULN); AST and ALT ≤ 1.5 times the upper limit of normal (ULN); alkaline phosphatase ≤ 5 times the upper limit of normal (ULN);
- •Adequate renal function: serum creatinine ≤ upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/min;
- •Visceral function: LVEF≥50%, the New York Society of Visceral Disease Association (NYHA) has a functional classification of I and II, and there is no unhealed wound on the body;
- •Sign the informed consent form.
- •Women should agree to use contraceptive measures (such as intrauterine device (IUD), contraceptives or condoms) during the study period and within 6 months after the end of the study; serum or urine pregnancy within 7 days before study entry The test is negative and must be a non-lactating patient; men should agree to patients who must use contraception during the study period and within 6 months after the end of the study period.
- •The patient voluntarily joined the study, signed an informed consent form, had good compliance, and was able to be followed up by the trial staff.
排除标准
- •Ewing's sarcoma, embryonic rhabdomyosarcoma, acinar rhabdomyosarcoma
- •Pregnant or breastfeeding women, or women who are fertile but have not taken contraceptive measures
- •Existing severe acute infection that has not been controlled; or having purulent or chronic infection, and the wound is protracted
- •Active hepatitis B or C
- •Have a history of other tumors within 5 years before treatment, except for cured cervical carcinoma in situ or skin basal cell carcinoma
- •Those who have participated in other drug clinical trials within 4 weeks
- •Patients with pre-existing severe heart disease, including: congestive heart failure, uncontrollable high-risk arrhythmia, unstable angina, myocardial infarction, severe heart valve disease and refractory hypertension, ventricular tachycardia, ventricular, Patients with atrial fibrillation, second-degree type II or third-degree atrioventricular block, myocardial infarction within 1 year, congestive heart failure, symptomatic coronary heart disease requiring medication
- •People with uncontrollable neurological or mental diseases or mental disorders, poor compliance, unable to cooperate and describe the treatment response; primary brain tumors or central nerve metastases have not been controlled, and have obvious intracranial hypertension or neuropsychiatry Symptoms
- •Past severe chronic skin diseases
- •People with bleeding tendency, evidence of hereditary bleeding constitution or coagulopathy
- •Have a clear history of allergy to chemotherapy drugs
研究组 & 干预措施
Pegylated liposomal doxorubicin + Anlotinib
Experimental
Pegylated liposomal doxorubicin 50mg/m2 intravenous infusion on the first day + Anlotinib 12mg/d orally, medication on days 8-21, one cycle every 21 days, 2~4 cycles
干预措施: Pegylated liposomal doxorubicin (Drug)
Pegylated liposomal doxorubicin + Anlotinib
Experimental
Pegylated liposomal doxorubicin 50mg/m2 intravenous infusion on the first day + Anlotinib 12mg/d orally, medication on days 8-21, one cycle every 21 days, 2~4 cycles
干预措施: Anlotinib (Drug)
结局指标
主要结局
ORR
时间窗: At the end of Cycle 3 (each cycle is 21 days)
Objective Response Rate
次要结局
- pCR rate(One year after the first intravenous drip)
- PFS(6 weeks after the first intravenous drip)
- OS(After the first intravenous drip,an average of 3 year through study completion)
研究者
Yong Chen
Chief Physician
Fudan University
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Phase I study of pegylated liposomal doxorubicin and cisplatin combination chemotherapy in patients with recurrent and refractory epithelial ovarian cancer.epithelial ovarian cancer, primary fallopian tube cancer, primary peritoneal cancerJPRN-UMIN000005798Cancer Institute Hospital18
Unknown
1 期
Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast CancerBreast CancerNCT03994107Peking Union Medical College40
Unknown
2 期
Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast CancerMetastatic Breast CancerNCT01451580TTY Biopharm47
终止
2 期
Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By SurgeryBreast CancerNCT00524459Roswell Park Cancer Institute6
Unknown
3 期
Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia:Acute Lymphoblastic LeukemiaNCT02070523Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.200